A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LD-DEX) versus Bortezomib and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma (MM)

ID Number 14-0405

Principal Investigator(s)
Sundar Jagannath

Department(s) or Division(s)
Hematology and Medical Oncology

Description

The purpose of this study is to see how well the combination of pomalidomide, bortezomib and dexamethasone works compared to the combination of bortezomib and dexamethasone. We will also be assessing how safe the combination of pomalidomide, bortezomib and dexamethasone is and how this combination treatment affects your quality of life compared t the combination of bortezomib and dexamethasone.



Contact Information
Lisa La
(212) 241-8615
(212) 824-7309

Recruiting Patients: Yes